Identification

Name
Dimetacrine
Accession Number
DB08996
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Dimetacrine (Istonil, Istonyl, Linostil, Miroistonil), also known as dimethacrine and acripramine, is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe and formerly in Japan for the treatment of depression.

Structure
Thumb
Synonyms
  • 3-(9,9-dimethylacridin-10-yl)-N,N-dimethyl-propan-1-amine
  • Dimetacrine
  • Istonil
  • Istonyl
  • Linostil
  • Miroistonil
Product Ingredients
IngredientUNIICASInChI Key
Dimetacrine bitartrateDVH164X0IF3759-07-7IIYKUJVECNNTEY-LREBCSMRSA-N
Dimetacrine tartrateNot AvailableNot AvailableNot applicable
Categories
UNII
O341NY501N
CAS number
4757-55-5
Weight
Average: 294.4338
Monoisotopic: 294.209598842
Chemical Formula
C20H26N2
InChI Key
RYQOGSFEJBUZBX-UHFFFAOYSA-N
InChI
InChI=1S/C20H26N2/c1-20(2)16-10-5-7-12-18(16)22(15-9-14-21(3)4)19-13-8-6-11-17(19)20/h5-8,10-13H,9,14-15H2,1-4H3
IUPAC Name
[3-(9,9-dimethyl-9,10-dihydroacridin-10-yl)propyl]dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12

Pharmacology

Indication
Not Available
Pharmacodynamics

Little is known about the pharmacology of dimetacrine.

Mechanism of action
TargetActionsOrganism
AAcetylcholinesterase
antagonist
Human
Absorption
Not Available
Volume of distribution

The highest concentrations of dimetacrine were found at 1 hour after administration but at 3 hours in brain, heart, lung, liver, spleen, kidney, skeletal muscle and adipose tissue of testes. (Carried out in mice, PMID 5312397).

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Approximately 70% of the doses were excreted in urine and feces within 2 days after treatment. (PMID 5312397)

Half life

Approximately 10 hours. (PMID 5312397)

Clearance
Not Available
Toxicity

Dimetacrine may induce severe cardiac toxicity in overdose. This property is unique among the tricyclic antidepressants.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Dimetacrine can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Dimetacrine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineDimetacrine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineDimetacrine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Dimetacrine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineDimetacrine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Dimetacrine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineDimetacrine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineDimetacrine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Dimetacrine.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Abediterol.Investigational
AcenocoumarolDimetacrine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AgmatineDimetacrine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AlogliptinThe serum concentration of Dimetacrine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Dimetacrine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Dimetacrine.Approved
AmitrazDimetacrine may decrease the antihypertensive activities of Amitraz.Vet Approved
AmobarbitalThe metabolism of Dimetacrine can be increased when combined with Amobarbital.Approved, Illicit
AmphetamineAmphetamine may increase the serotonergic activities of Dimetacrine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Dimetacrine can be increased when it is combined with Amprenavir.Approved, Investigational
Antithrombin III humanThe serum concentration of Dimetacrine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Dimetacrine can be increased when it is combined with Apixaban.Approved
ApomorphineDimetacrine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineDimetacrine may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Dimetacrine can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Dimetacrine can be increased when it is combined with Argatroban.Approved, Investigational
AsunaprevirThe serum concentration of Dimetacrine can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Dimetacrine can be increased when it is combined with Atazanavir.Approved, Investigational
BambuterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Dimetacrine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Dimetacrine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Dimetacrine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Dimetacrine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Dimetacrine.Withdrawn
BenzamidineThe serum concentration of Dimetacrine can be increased when it is combined with Benzamidine.Experimental
BenzphetamineDimetacrine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
BethanidineDimetacrine may decrease the antihypertensive activities of Bethanidine.Approved
BitolterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Bitolterol.Withdrawn
BivalirudinThe serum concentration of Dimetacrine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Dimetacrine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BrimonidineDimetacrine may decrease the antihypertensive activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Dimetacrine.Experimental
BromocriptineDimetacrine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Dimetacrine can be decreased when combined with Bupropion.Approved
CamostatThe serum concentration of Dimetacrine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Dimetacrine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Dimetacrine can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Dimetacrine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Dimetacrine can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Dimetacrine.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Celiprolol.Approved, Investigational
ChlorphentermineDimetacrine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChymostatinThe serum concentration of Dimetacrine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Dimetacrine can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Dimetacrine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Dimetacrine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Dimetacrine can be increased when it is combined with Cinacalcet.Approved
CirazolineDimetacrine may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Citalopram.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClonidineDimetacrine may decrease the antihypertensive activities of Clonidine.Approved
ClorindioneDimetacrine may increase the anticoagulant activities of Clorindione.Experimental
Dabigatran etexilateThe serum concentration of Dimetacrine can be increased when it is combined with Dabigatran etexilate.Approved
DarexabanThe serum concentration of Dimetacrine can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Dimetacrine can be increased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Dimetacrine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Dimetacrine can be increased when it is combined with Delapril.Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Desmopressin.Approved
DetomidineDimetacrine may decrease the antihypertensive activities of Detomidine.Vet Approved
DexmedetomidineDimetacrine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Dimetacrine.Approved, Investigational
DextroamphetamineDimetacrine may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DicoumarolDimetacrine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDimetacrine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineDimetacrine may decrease the antihypertensive activities of Dihydroergotamine.Approved, Investigational
DiphenadioneDimetacrine may increase the anticoagulant activities of Diphenadione.Experimental
DipivefrinDimetacrine may decrease the antihypertensive activities of Dipivefrin.Approved
DL-MethylephedrineDimetacrine may decrease the antihypertensive activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Dobutamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Doxofylline.Approved, Investigational
DroxidopaDimetacrine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Dimetacrine.Approved
EcabetThe serum concentration of Dimetacrine can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Dimetacrine can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Dimetacrine can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Dimetacrine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Dimetacrine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Dimetacrine can be increased when it is combined with Enalkiren.Experimental
EphedraDimetacrine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineDimetacrine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovineDimetacrine may increase the vasopressor activities of Ergonovine.Approved
ErgotamineDimetacrine may decrease the antihypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Escitalopram.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Etafedrine.Approved
Ethyl biscoumacetateDimetacrine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateDimetacrine may decrease the antihypertensive activities of Etomidate.Approved
FaldaprevirThe serum concentration of Dimetacrine can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Fenoterol.Approved, Investigational
FluindioneDimetacrine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dimetacrine.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dimetacrine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Dimetacrine can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Dimetacrine can be increased when it is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Dimetacrine.Approved, Investigational, Vet Approved
GabexateThe serum concentration of Dimetacrine can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Dimetacrine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GepefrineDimetacrine may increase the stimulatory activities of Gepefrine.Experimental
GM6001The serum concentration of Dimetacrine can be increased when it is combined with GM6001.Experimental
GuanabenzDimetacrine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineDimetacrine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HarmalineHarmaline may increase the serotonergic activities of Dimetacrine.Experimental
HexobarbitalThe metabolism of Dimetacrine can be increased when combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the serotonergic activities of Dimetacrine.Experimental
HydroxyamphetamineDimetacrine may increase the stimulatory activities of Hydroxyamphetamine.Approved
IdraparinuxThe serum concentration of Dimetacrine can be increased when it is combined with Idraparinux.Investigational
ImidaprilThe serum concentration of Dimetacrine can be increased when it is combined with Imidapril.Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Indacaterol.Approved
IndinavirThe serum concentration of Dimetacrine can be increased when it is combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dimetacrine.Approved, Investigational
Iofetamine I-123Dimetacrine may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Dimetacrine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Dimetacrine.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Dimetacrine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Dimetacrine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneDimetacrine may increase the vasopressor activities of Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Isoprenaline.Approved, Investigational
IxazomibThe serum concentration of Dimetacrine can be increased when it is combined with Ixazomib.Approved, Investigational
LepirudinThe serum concentration of Dimetacrine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Dimetacrine can be increased when it is combined with Letaxaban.Investigational
LevonordefrinDimetacrine may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Levosalbutamol.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Dimetacrine.Approved
LinagliptinThe serum concentration of Dimetacrine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Dimetacrine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Dimetacrine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Dimetacrine.Approved
LisdexamfetamineDimetacrine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Dimetacrine can be increased when it is combined with Lisinopril.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Dimetacrine.Experimental
LofexidineDimetacrine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Dimetacrine can be increased when it is combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Dimetacrine can be increased when it is combined with Lorpiprazole.Approved
MebanazineMebanazine may increase the serotonergic activities of Dimetacrine.Withdrawn
MedetomidineDimetacrine may decrease the antihypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Dimetacrine can be increased when it is combined with Melagatran.Experimental
MephedroneDimetacrine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineDimetacrine may increase the vasopressor activities of Mephentermine.Approved
MetaraminolDimetacrine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethamphetamineDimetacrine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Dimetacrine can be increased when combined with Methohexital.Approved
MethoxamineDimetacrine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyphenamineDimetacrine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethyldopaDimetacrine may decrease the antihypertensive activities of Methyldopa.Approved
Methylene blueDimetacrine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Dimetacrine.Approved, Investigational
MethylphenobarbitalThe metabolism of Dimetacrine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Dimetacrine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dimetacrine.Approved
MidodrineDimetacrine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineDimetacrine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MinaprineMinaprine may increase the serotonergic activities of Dimetacrine.Approved
MMDADimetacrine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Dimetacrine.Approved, Investigational
MoexiprilThe serum concentration of Dimetacrine can be increased when it is combined with Moexipril.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Dimetacrine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Dimetacrine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Dimetacrine can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineDimetacrine may decrease the antihypertensive activities of Naphazoline.Approved
NelfinavirThe serum concentration of Dimetacrine can be increased when it is combined with Nelfinavir.Approved
NialamideNialamide may increase the serotonergic activities of Dimetacrine.Withdrawn
NicorandilDimetacrine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NorepinephrineDimetacrine may decrease the antihypertensive activities of Norepinephrine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Dimetacrine.Withdrawn
OlodaterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Dimetacrine can be increased when it is combined with Omapatrilat.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Orciprenaline.Approved
OtamixabanThe serum concentration of Dimetacrine can be increased when it is combined with Otamixaban.Investigational
OxymetazolineDimetacrine may decrease the antihypertensive activities of Oxymetazoline.Approved, Investigational
PaliperidoneDimetacrine may decrease the antihypertensive activities of Paliperidone.Approved
PargylinePargyline may increase the serotonergic activities of Dimetacrine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dimetacrine.Approved, Investigational
PentobarbitalThe metabolism of Dimetacrine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideDimetacrine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Dimetacrine can be increased when it is combined with Perindopril.Approved
PF-00610355The risk or severity of adverse effects can be increased when Dimetacrine is combined with PF-00610355.Investigational
PhendimetrazineDimetacrine may increase the vasopressor activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Dimetacrine.Approved
PhenindioneDimetacrine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Dimetacrine.Withdrawn
PhenobarbitalThe metabolism of Dimetacrine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Dimetacrine.Withdrawn
PhenprocoumonDimetacrine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineDimetacrine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineDimetacrine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhosphoramidonThe serum concentration of Dimetacrine can be increased when it is combined with Phosphoramidon.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Dimetacrine.Approved
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Dimetacrine.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Dimetacrine.Withdrawn
PrimidoneThe metabolism of Dimetacrine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Dimetacrine can be increased when it is combined with Prinomastat.Investigational
ProcaineProcaine may increase the serotonergic activities of Dimetacrine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Dimetacrine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Procaterol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Protokylol.Approved, Vet Approved
PseudoephedrineDimetacrine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuinaprilThe serum concentration of Dimetacrine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineDimetacrine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
RacecadotrilThe serum concentration of Dimetacrine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineDimetacrine may decrease the antihypertensive activities of Racepinephrine.Approved
RamiprilThe serum concentration of Dimetacrine can be increased when it is combined with Ramipril.Approved
RasagilineRasagiline may increase the serotonergic activities of Dimetacrine.Approved
RemikirenThe serum concentration of Dimetacrine can be increased when it is combined with Remikiren.Approved
RisperidoneDimetacrine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronDimetacrine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Dimetacrine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Dimetacrine can be increased when it is combined with Rivaroxaban.Approved
RomifidineDimetacrine may decrease the antihypertensive activities of Romifidine.Vet Approved
RopiniroleDimetacrine may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
S-3304The serum concentration of Dimetacrine can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Dimetacrine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Dimetacrine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Dimetacrine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Dimetacrine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Dimetacrine.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Dimetacrine.Approved
SimeprevirThe serum concentration of Dimetacrine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Dimetacrine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Dimetacrine can be increased when it is combined with Sivelestat.Investigational
Sodium phosphate, monobasicThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Sodium phosphate.Approved
SpiraprilThe serum concentration of Dimetacrine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Dimetacrine can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
TelaprevirThe serum concentration of Dimetacrine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TemocaprilThe serum concentration of Dimetacrine can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Dimetacrine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Terbutaline.Approved
TetryzolineDimetacrine may increase the vasopressor activities of Tetryzoline.Approved
ThiamylalThe metabolism of Dimetacrine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Dimetacrine can be increased when combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Dimetacrine can be increased when it is combined with Thiorphan.Experimental
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Dimetacrine.Approved
TioclomarolDimetacrine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Dimetacrine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineDimetacrine may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
ToloxatoneToloxatone may increase the serotonergic activities of Dimetacrine.Approved
TramadolDimetacrine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Dimetacrine can be increased when it is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the serotonergic activities of Dimetacrine.Approved, Investigational
UbenimexThe serum concentration of Dimetacrine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Dimetacrine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Dimetacrine can be increased when it is combined with Valproic Acid.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dimetacrine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Vilanterol.Approved
VildagliptinThe serum concentration of Dimetacrine can be increased when it is combined with Vildagliptin.Approved, Investigational
WarfarinDimetacrine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Dimetacrine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineDimetacrine may decrease the antihypertensive activities of Xylazine.Vet Approved
XylometazolineDimetacrine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Dimetacrine.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Dimetacrine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZofenoprilThe serum concentration of Dimetacrine can be increased when it is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

GB933875

General References
  1. Ishitani R, Saito E, Kitagawa H: The pharmacological studies on dimetacrine. I. Studies on the absorption, distribution and excretion of H3-labeled dimetacrine in the rat. Jpn J Pharmacol. 1970 Sep;20(3):432-8. [PubMed:5312397]
External Links
KEGG Drug
D02565
KEGG Compound
C12959
PubChem Compound
94280
PubChem Substance
310264957
ChemSpider
85085
ChEBI
135233
ChEMBL
CHEMBL1328913
Wikipedia
Dimetacrine
ATC Codes
N06AA18 — Dimetacrine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3284454No1966-11-081986-11-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)155-156U.S. Patent 3,284,454.
Predicted Properties
PropertyValueSource
Water Solubility0.0343 mg/mLALOGPS
logP4.96ALOGPS
logP4.42ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.52 m3·mol-1ChemAxon
Polarizability35.87 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Benzoquinolines
Direct Parent
Acridines
Alternative Parents
Alkyldiarylamines / Benzenoids / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Acridine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Ishitani R, Sato T, Suga T, Kitagawa H: Studies on the ultrastructural distribution of H 3 -dimetacrine in rat cerebral cortex. Jpn J Pharmacol. 1972 Jun;22(3):313-23. [PubMed:4539395]

Drug created on June 16, 2014 13:04 / Updated on July 02, 2018 20:41